Table.
The retinal thickness and visual function data pre and post-treatment with topical dorzolamide 2% formulation in the study cohort
| Retinal thickness (μm) |
ETDRS log MAR visual acuity (Snellen acuity) |
MP sensitivity (dB) |
Log P-R CS | Log grating CS | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OD | OS | OD | OS | OD | OS | OD | OS | OD | OS | ||
| Patient 1 | Baseline | 310 | 302 | 0.50 (20/50−2) | 0.48 (20/60−2) | 2.3 | 3.0 | 1.20 | 1.05 | 0.37 (binocular) | |
|
Two-month
follow-up |
249 | 254 | 0.36 (20/50+1) | 0.28 (20/50+1) | 2.6 | 3.4 | 1.20 | 1.05 | 0.81 (binocular) | ||
|
Five-month
follow-up |
236 | 211 | 0.24 (20/40+1) | 0.16 (20/30) | 3.1 | 3.3 | 1.20 | 1.20 | 0.64 (binocular) | ||
| Patient 2 | Baseline | 390 | 395 | 0.46((20/50−2) | 0.70 (20/200) | 3.0 | 1.6 | 1.05 | 0.90 | 0.64 | † |
|
Two-month
follow-up |
276 | 261 | 0.40 (20/50−1) | 0.60 (20/80+1) | 3.3 | 1.5 | 1.05 | 0.90 | 0.89 | ‡ | |
|
Five-month
follow-up |
248 | 253 | 0.44 (20/50−2) | 0.60 (20/80−1) | ** | 1.1 | 1.05 | 0.75 | 0.68 | ‡ | |
*
ETDRS= Early Treatment Diabetic Retinopathy Study; MP= Microperimetry; P-R CS= Pelli-Robson Letter Contrast Sensitivity; Grating CS= 2.0 cpd Grating Contrast Sensitivity.
**
The patient could not complete the test due to eye fatigue
†
Sensitivity was below measurable limits
‡
Sensitivity not measured